Samplix
Samplix develops Xdrop, a droplet microfluidics platform for functional single-cell analysis. It encloses individual living cells and assay reagents in millions of double-emulsion droplets, which serve as miniature reaction vessels and can be analyzed and sorted using standard flow cytometry and cell-sorting equipment. The company says the platform supports applications including antibody discovery and cell line development. Samplix announced a €25 million first close of a financing round, including new capital and shareholder convertible bonds, to strengthen its balance sheet and broaden commercial adoption.
2026-11-03
DropGenie
DropGenie is a biotech startup developing a digital microfluidics platform to automate laboratory research workflows. The technology uses electrical signals to manipulate liquid droplets on a chip and is described as requiring up to 100 times fewer cells and less reagent than traditional methods. The company raised $5 million in a seed-plus financing round, which it plans to use to advance the platform. A commercial launch is scheduled for the second quarter of 2027, according to the supplied text.
2026-10-26
Droplet Scientific
University of Southampton spinout Droplet Scientific is developing a microfluidic and optical platform for continuous biochemical monitoring at hospital bedsides. The system automates biomarker sampling every 20 seconds to provide near-real-time data, with its AnalyteX product initially targeting neuroscience intensive care units as an alternative to intermittent laboratory blood tests. The company raised £1.5 million in the first close of a pre-seed round to support product development, regulatory certification, and team expansion.
2026-10-14
Sava Technologies
Sava Technologies is a London-based health technology startup developing wearable biosensor microsensors that continuously and painlessly measure molecules just beneath the skin. Its first application is continuous glucose monitoring, with a platform designed to track additional biomarkers. The company raised a $36 million Series B to support manufacturing scale-up and commercial readiness, and named Ascensia as its commercialization and distribution partner in Europe. Sava plans a pivotal clinical study and is targeting CE approval for non-adjunctive glucose monitoring use.
2026-10-09
SpectaCell
SpectaCell is a Ghent-based spinout from imec, VIB, and Ghent University developing a chip-based cell-analysis platform for cell therapy testing. Its system combines imaging and data analysis to track live cell interactions over time without fluorescent labels, helping developers assess how immune cells respond to targets. The company says its instrument uses cartridges and is designed to support testing from early research through manufacturing quality checks. Following its launch and seed financing, SpectaCell plans further development and commercialization with pharmaceutical and biotechnology partners.
2026-10-07
CellsBin
CellsBin is developing a Rare-Cell Intelligence Platform that combines microfluidics, multimodal imaging, single-cell analysis, and artificial intelligence to make rare cells measurable and actionable. The company says the platform aims to reveal signals that conventional methods may miss. Initial applications focus on monitoring cell and gene therapies and studying hematologic cancers. CellsBin announced a Series A financing led by 108 BioCapital and plans to use the proceeds to advance its product roadmap, commercial adoption, partnerships, clinical evidence, and team.
2026-09-22
Picodya
Picodya develops cartridge-based diagnostic systems built around its PicoFluidics technology. Its B-Matrix platform combines small-volume fluid handling, image processing and automation to run molecular assays and immunoassays for clinical and research workflows.
2026-09-14
Qureator
Qureator develops Curiochips, a three-dimensional organ-on-chip platform for modeling human biology. The company combines engineered tissue systems with data analysis to study disease and treatment responses during preclinical drug development.
2026-09-14
1DROP
1DROP combines capillary-driven microfluidic chips with optical detection for portable diagnostics. Its chips integrate sample handling, reagents and reaction chambers to measure multiple biomarkers from small samples without separate fluid-control equipment.
2026-09-14
Baebies
Baebies develops diagnostic platforms based on digital microfluidics. Its systems move tiny droplets with electrically controlled surfaces to run different assay types, including molecular, chemistry, coagulation and immunoassay tests, within compact instruments.
2026-09-14
LIOM
LIOM is developing wearable sensing technology for non-invasive biochemical monitoring, beginning with glucose. Formerly called Spiden, the company is working toward continuous measurements through the skin; its platform remains a development effort rather than an established consumer diagnostic.
2026-09-14
DLOC Biosystems
DLOC Biosystems develops organ-on-chip devices and automated systems for connecting multiple tissue models. Its platforms combine three-dimensional scaffolds, controlled fluid handling and tissue measurements to support preclinical studies of drug effects and organ interactions.
2026-09-14